Srdan Verstovsek, MD, PhD of the University of Texas MD Anderson Cancer Center, Houston, TX discusses highlights in myeloproliferative neoplasm (MPN) research at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. As the EHA meeting is becoming more popular, more sessions on MPN are run. The sessions on the biology are dissecting the cause of hyperactive JAK/STAT pathway, which is abnormal in MPN patients. Further, he talks about prognostication, i.e. understanding these mutations and their effect. In terms of clinical studies, he highlights the RESPONSE-2 (NCT02038036) that was complementary to an earlier study that led to the approval of ruxolitinib, a JAK inhibitor, for polycythemia vera (PV) in second-line.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates